SG152288A1 - Management of breakthrough bleeding in extended hormonal contraceptive regimens - Google Patents

Management of breakthrough bleeding in extended hormonal contraceptive regimens

Info

Publication number
SG152288A1
SG152288A1 SG200902990-1A SG2009029901A SG152288A1 SG 152288 A1 SG152288 A1 SG 152288A1 SG 2009029901 A SG2009029901 A SG 2009029901A SG 152288 A1 SG152288 A1 SG 152288A1
Authority
SG
Singapore
Prior art keywords
management
hormonal contraceptive
breakthrough bleeding
contraceptive regimens
extended
Prior art date
Application number
SG200902990-1A
Other languages
English (en)
Inventor
Andreas Sachse
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG152288(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of SG152288A1 publication Critical patent/SG152288A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
SG200902990-1A 2004-04-30 2005-04-29 Management of breakthrough bleeding in extended hormonal contraceptive regimens SG152288A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56644304P 2004-04-30 2004-04-30
US57502404P 2004-05-28 2004-05-28
US57719904P 2004-06-07 2004-06-07
US63838004P 2004-12-27 2004-12-27
US66006805P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
SG152288A1 true SG152288A1 (en) 2009-05-29

Family

ID=35056905

Family Applications (2)

Application Number Title Priority Date Filing Date
SG200902990-1A SG152288A1 (en) 2004-04-30 2005-04-29 Management of breakthrough bleeding in extended hormonal contraceptive regimens
SG10201701904TA SG10201701904TA (en) 2004-04-30 2005-04-29 Management of breakthrough bleeding in extended hormonal contraceptive regimens

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201701904TA SG10201701904TA (en) 2004-04-30 2005-04-29 Management of breakthrough bleeding in extended hormonal contraceptive regimens

Country Status (29)

Country Link
US (3) US8163721B2 (fr)
EP (1) EP1747001B1 (fr)
JP (4) JP2007535519A (fr)
KR (4) KR20070004919A (fr)
CN (1) CN103127156A (fr)
AR (1) AR048722A1 (fr)
AU (1) AU2005237255B2 (fr)
BR (1) BRPI0510493A (fr)
CA (1) CA2562296A1 (fr)
CR (1) CR8709A (fr)
DK (1) DK1747001T3 (fr)
EA (2) EA031227B1 (fr)
EC (1) ECSP066999A (fr)
ES (1) ES2704999T3 (fr)
HU (1) HUE041475T2 (fr)
IL (1) IL178458A (fr)
LT (1) LT1747001T (fr)
MX (1) MXPA06012567A (fr)
MY (1) MY151322A (fr)
NO (1) NO341685B1 (fr)
NZ (1) NZ586107A (fr)
PA (1) PA8631801A1 (fr)
PE (1) PE20060467A1 (fr)
SG (2) SG152288A1 (fr)
SI (1) SI1747001T1 (fr)
SV (1) SV2006002100A (fr)
TW (1) TWI374735B (fr)
UY (1) UY28875A1 (fr)
WO (1) WO2005105103A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070088010A1 (en) * 2005-10-17 2007-04-19 Doris Huebler Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
EP1977752A1 (fr) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Composition pharmaceutique destinée à réduire l'endométriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
US20100120707A1 (en) * 2008-09-16 2010-05-13 Playtex Products, Llc Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same
CA2740004A1 (fr) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Administration transdermique
US9198876B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
CA2740005C (fr) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Delivrance transdermique
EP2410859A4 (fr) 2009-03-27 2013-03-13 Agile Therapeutics Inc Administration transdermique
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (fr) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Procédé de préparation d'estetrol
US10894014B2 (en) 2015-06-18 2021-01-19 Estetra Sprl Orodispersible tablet containing Estetrol
SI3310346T1 (sl) 2015-06-18 2021-07-30 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
PE20231714A1 (es) 2015-06-18 2023-10-23 Estetra Sprl Unidad de dosificacion orodispersable que contiene un componente estetrol
UA123098C2 (uk) 2015-06-18 2021-02-17 Естетра Спрл Диспергована у порожнині рота одиниця дозування, що містить естетрольний компонент
AU2016282863B2 (en) * 2015-06-23 2021-05-27 Laboratorios Leon Farma Sa Drospirenone-based contraceptive for a female patient affected with excess weight
CA3178291A1 (fr) 2016-08-05 2018-04-12 Estetra Srl Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles
EP4094766A1 (fr) 2016-09-30 2022-11-30 Myovant Sciences GmbH Méthodes de traitement des fibromes utérins et de l'endométriose
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244096A (en) 1988-04-22 1993-09-14 Stoner Fred L Preventive treatment kit against sexually transmitted disease
AU3473193A (en) 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US6451778B1 (en) 1996-07-26 2002-09-17 Wyeth Oral contraceptive
ATE271386T1 (de) 1996-07-26 2004-08-15 Wyeth Corp Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält
US5842441A (en) 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
JP4354667B2 (ja) 1999-08-31 2009-10-28 バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US8501720B2 (en) 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea

Also Published As

Publication number Publication date
AR048722A1 (es) 2006-05-17
PA8631801A1 (es) 2006-11-09
BRPI0510493A (pt) 2007-11-13
NZ586107A (en) 2012-05-25
SV2006002100A (es) 2006-02-15
ES2704999T3 (es) 2019-03-21
JP6134491B2 (ja) 2017-05-24
MY151322A (en) 2014-05-15
UY28875A1 (es) 2005-11-30
EA016625B1 (ru) 2012-06-29
EA201200377A8 (ru) 2018-01-31
KR101812160B1 (ko) 2017-12-27
KR20130022425A (ko) 2013-03-06
US20120202779A1 (en) 2012-08-09
AU2005237255A1 (en) 2005-11-10
LT1747001T (lt) 2019-01-25
KR20160150113A (ko) 2016-12-28
CR8709A (es) 2007-08-28
SI1747001T1 (sl) 2019-02-28
JP2017048253A (ja) 2017-03-09
IL178458A0 (en) 2008-04-13
KR20150058555A (ko) 2015-05-28
NO20065499L (no) 2006-11-29
ECSP066999A (es) 2006-12-29
US8163721B2 (en) 2012-04-24
TWI374735B (en) 2012-10-21
PE20060467A1 (es) 2006-06-11
WO2005105103A2 (fr) 2005-11-10
JP6153967B2 (ja) 2017-06-28
KR20070004919A (ko) 2007-01-09
EA031227B1 (ru) 2018-12-28
JP2015187157A (ja) 2015-10-29
US20150174142A1 (en) 2015-06-25
CA2562296A1 (fr) 2005-11-10
US20050250747A1 (en) 2005-11-10
JP2007535519A (ja) 2007-12-06
JP2013018787A (ja) 2013-01-31
WO2005105103A3 (fr) 2006-09-08
NO341685B1 (no) 2017-12-18
IL178458A (en) 2016-08-31
MXPA06012567A (es) 2006-12-15
DK1747001T3 (en) 2019-02-04
CN103127156A (zh) 2013-06-05
HUE041475T2 (hu) 2019-05-28
SG10201701904TA (en) 2017-05-30
EP1747001A2 (fr) 2007-01-31
AU2005237255B2 (en) 2011-07-07
EA200601908A1 (ru) 2007-04-27
EP1747001B1 (fr) 2018-10-10
EA201200377A1 (ru) 2012-08-30
TW200603781A (en) 2006-02-01

Similar Documents

Publication Publication Date Title
MY151322A (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens
EP1803552A4 (fr) Film formant barriere aux gaz destine a un usage medical et sacs medicaux fabriques avec ce film
TW200744667A (en) Foamable suspension gel
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
HK1103026A1 (en) Pharmaceutical vaginal gel comprising tenofovir
AP2004003046A0 (en) Dosage regimen and pharmaceutical composition for emergency contraception.
HK1205468A1 (en) Extended estrogen dosing contraceptive regimen
IL181445A0 (en) Use of (halobenzyloxy)benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium selective modulators
EP1819323A4 (fr) Composition pharmaceutique renfermant un agent d'anti-nucleation
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
HK1109579A1 (en) Pharmaceutical composition comprising drospirenone and ethynylestradiol
EP1934115A4 (fr) Plaquette de distribution et de stockage de medicaments a l'epreuve des enfants et plaquette alveolaire scellee
UA91190C2 (ru) Контроль прорывных кровотечений при пролонгированном режиме приема гормональных контрацептивов
EP2234491A4 (fr) Schémas posologiques, compositions pharmaceutiques et emballages pour une contraception d'urgence
JO3731B1 (ar) تدبير نزيف مفاجئ في انظمة موانع حمل هرمونية
CU20060204A7 (es) Tratamiento de la hemorragia de disrupción en regímenes anticonceptivos extendidos
TW200605891A (en) Use of 7-t-butoxyiminomethylcamptothecin for the preparation of a medicament for the treatment of uterine neoplasms
HU0500288D0 (en) Intra-uterine contraceptive
HU0500490D0 (en) Intra-uterine contraceptive
RU2006106570A (ru) Спермицидное средство
GB0417126D0 (en) Blister pack leak detection-presentation
CL2008001881A1 (es) Composicion farmaceutica que comprende ibuprofeno y un antihistaminico seleccionado de astemizol, azatidina, azelastina, acrivastina, bromfeniramina, clorfeniramina, clemastina, entre otros y que no comprende un descongestionante; procedimiento de pr
GB0310958D0 (en) Reversible contraceptive device for use in the vas deferens